Business
Patient Six Cancer-Free Twelve Months After Single Anti-Cancer Treatment
Results of Phase Ib Non-Muscle Invasive Bladder Cancer ("NMIBC") Clinical Study Demonstrate ...
About this update from Theralase Technologies Inc.
[{"type":"text","content":"Patient Six Cancer-Free Twelve Months After Single Anti-Cancer TreatmentResults of Phase Ib Non-Muscle Invasive Bladder Cancer (\"NMIBC\") Clinical Study Demonstrate a 66% Complete Response (\"CR\") at the Therapeutic Dose (0.70 mg/cm2) 360 Days Post TreatmentTORONTO, ON / ACCESSWIRE / April 2, 2019 / Theralase Technologies Inc. (\"Theralase®\" or the \"Company\") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (\"PDCs\") and their associated drug formulations intended to safely and effectively destroy various cancers is pleased to report that patient six, enrolled and treated in the recently completed Phase Ib NMIBC Clinical Study (\"Study\"), has demonstrated a CR with no tumour recurrence, progression or presence of NMIBC disease at the 360 day clinical and cystoscopy assessment.The Study's purpose was to evaluate TLD-1433, Theralase's lead PDC, for the primary endpoint of safety and tolerability, a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment. The Study was successfully completed with patient five and six demonstrating achievement of the primary, secondary and exploratory endpoints at 90 and 180 days, when treated with the Therapeutic Dose.The Company is pleased to report that patient five and six have continued to demonstrate no tumour recurrence, progression or presence of NMIBC disease at 360 days post treatment during their scheduled clinical and cystoscopy assessment.This latest data validates the strong efficacy signal that the Company has received after only a single Anti-Cancer Treatment (\"ACT\") in the completed Study, representing a 66% CR in the Therapeutic Dose group.Three patients (patients four, five and six) were enrolled and treated at the Therapeutic Dose (0.70 mg/cm2), with patient 4 successfully achieving the primary and secondary endpoints at 90 days post treatment; however, the patient was diagnosed with pre-existing and non-Study related metastatic disease and was excluded from further study evaluation. Theralase's ACT involved the intravesical instillation of a water-based solution of Theralase's lead anti-cancer PDC, TLD-1433, via a catheter inserted throug...